Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pregnant women are eligible for inclusion into the Very High Risk Group if they:~* are PLA-1 (platelet antigen A1) negative and have known platelet incompatibility with their fetus~* have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation (as best as could be estimated)~* are less than 19 weeks gestation~Pregnant women are eligible for inclusion into the High Risk Group if they:~* are PLA-1 negative and have known platelet incompatibility with the fetus~* have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation (as best as could be estimated)~* are between 12-30 weeks gestation~Pregnant women are eligible for inclusion into the Standard Risk Group if they:~* are PLA-1 negative and have known platelet incompatibility with the fetus~* have not had a previous child who suffered an antenatal hemorrhage~* are between 20-30 weeks gestation~Exclusion Criteria:~Women are not eligible for inclusion into the Very High Risk Group if they:~* have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation~* are greater than 19 weeks gestation~Women are not eligible for inclusion into the High Risk Group if they:~* have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation~* are greater than 30 weeks gestation~Women are not eligible for inclusion into the Standard Risk Group if they:~* have had a previous child who suffered an antenatal hemorrhage~* are greater than 30 weeks gestation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IVIG x 2 (Type: EXPERIMENTAL): IVIG 2 g/kg/wk divided into 2 infusions per week for women with a fetus affected by FNAIT
- IVIG x 1 + prednisone (Type: EXPERIMENTAL): IVIG 1 g/kg/wk in 1 infusion per week + prednisone 0.5 mg po daily for women with a fetus affected by FNAIT

Based on this trial design, predict the completion outcome and termination type (if applicable).